Alcon

a Novartis company

Sponsor

Alcon Research, Ltd.

Generic Drug Name

Anecortave Acetate 15 mg (0.5 mL of 30 mg/mL Anecortave Acetate sterile suspension)

Trial Indication(s)

Treatment of exudative age-related macular degeneration

Protocol Number

C-03-15

Protocol Title

An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Juxtascleral Injections of Anecortave Acetate 15 mg in Patients with Subfoveal Exudative Age-Related Macular Degeneration (AMD)

Clinical Trial Phase

Phase 3

Study Start/End Dates

18 Jun 2003 to 19 Oct 2008

Reason for Termination

Product development was terminated for this use.

Study Design/Methodology

This was an open-label, multi-center, rollover study.

Alcon

a Novartis company

Centers

Subjects were recruited from 26 investigational sites located in US (10), UK (4), Hungary (2), Netherlands (2), France (1), Germany (1), Sweden (1), Northern Ireland (1), Poland (1), Portugal (1), Spain (1) and Italy (1).

Objectives

The objective of this study was to investigate the long-term efficacy and safety of Anecortave Acetate 15 mg (0.5 mL of 30 mg/mL Anecortave Acetate Sterile Suspension) in patients who were actively enrolled with at least 24 months of continuous participation in C-98-03, or who had completed an Alcon Anecortave Acetate Phase 3 study prior to screening for C-03-15.

Test Product, Dose, and Mode of Administration

Test Product: Anecortave Acetate 15 mg (AA 15 mg)
Dose: One 0.5 mL injection of 30 mg/mL Anecortave Acetate Sterile Suspension
Mode of Administration: One injection into the posterior juxtascleral depot at 6 month intervals

Statistical Methods

The primary statistical objective was to describe the long-term efficacy and safety of AA 15 mg using descriptive statistics. One population was identified and evaluated:

- Safety: included all patients who received study drug

Study Population: Key Inclusion/Exclusion Criteria

Inclusion criteria:

- Patients with subfoveal exudative AMD who were actively enrolled, with at least 24 months of continuous participation, in Alcon study C-98-03, or who had completed an Alcon Anecortave Acetate Phase 3 study prior to screening for this studyMeets protocol-specified criteria for qualification and contraception
- Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures

Exclusion criteria:

- Use of medications outside protocol-specified parameters

- Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:
  1. the safety or well-being of the participant or study staff
  2. the safety or well-being of the participant's offspring (such as through or breast-feeding)
  3. the analysis of results

Participant Flow Table

	All Patients	
	N	**%**
Started	111	100.0
Discontinued before Month 24	54	49.0
Completed	0	0
Reasons for discontinuation before Month 24		
Physician decision	27	24.3
Patient decision unrelated to Adverse Event (AE)	14	12.6
Adverse event	9	8.1
Study termination	4	3.6
Reasons for discontinuation after Month 24		
Study termination	57	51.0

Baseline Characteristics

	All Patients	
	N	**%**
Total	111	100.0
Age		
Adults (50 - < 65 years)	7	6.3
Elderly (≥ 65 years)	104	93.7
Sex		

Male	59	53.2
Female	52	46.8

Summary of Efficacy

Primary Outcome Measures

Proportion of Patients with < 3-Line Visual Acuity Loss
(Change Relative to Previous Anecortave Acetate Study Eligibility)
(All Patients)

	AA 15 mg			
	< 3-Line Loss		≥ 3-Line Loss	
	N	%	N	%
Month 6	57	54.3	48	45.7
Month 12	39	48.1	42	51.9
Month 18	32	49.2	33	50.8
Month 24	27	50.0	27	50.0

AA = Anecortave Acetate
Note: 2 patients had missing visual acuity data at Month 24 and 1 patient had missing baseline data from the previous Anecortave Acetate study

Alcon

a Novartis company

Change from Baseline in ETDRS Visual Acuity Score
(Change Relative to Baseline of Current Study)
(All Patients)

	Mean	Std	N	Min	Max
Month 6	-0.8	8.4	106	-65	17
Month 12	-2.9	9.8	82	-59	14
Month 18	-2.6	11.6	66	-58	12
Month 24	-4.2	12.9	55	-58	12

AA = Anecortave Acetate
Note: 2 patients had missing visual acuity data at Month 24

Change from Baseline in ETDRS Visual Acuity Score
(Change Relative to Previous Anecortave Acetate Study)
(All Patients)

	Mean	**Std**	**N**	**Min**	**Max**
Month 6	-13.6	18.1	105	-59	27
Month 12	-14.9	18.2	81	-58	25
Month 18	-13.9	19.1	65	-56	28
Month 24	-14.7	17.0	54	-59	25

AA = Anecortave Acetate
Note: 2 patients had missing visual acuity data at Month 24 and 1 patient had missing baseline data from the previous Anecortave Acetate study

Secondary Outcome Measures

None to report.

Alcon

a Novartis company

Summary of Safety

No treatment limiting safety issues were identified in patients with exudative age-related macular degeneration administered Anecortave Acetate 15 mg every 6 months for up to 2 years based upon a review of adverse events and an assessment of ocular health, including visual acuity.

Serious Adverse Events

All 111 enrolled patients were evaluable for the safety analysis. Overall, 5 (4.5%) patients died and 26 (23.4%) patients experienced other serious AEs during the study. None of the deaths or other serious AEs were considered related to the use of study drug or to the posterior juxtascleral depot (PJD) procedure.

Other Relevant Findings

Separate from the 5 patients who died, 4 other patients discontinued study participation due to 1 or more AEs, including 1 patient who experienced a serious AE (depression) and 3 patients who experienced nonserious AEs. The nonserious events that led to patient discontinuation included hyphema, retinal hemorrhage, visual acuity reduced, vitreous hemorrhage (all severe events, reported by 1 patient), retinal neovascularization (a mild event reported by 1 patient) and myocardial ischemia (a moderate event reported by 1 patient). None of the events that resulted in patient discontinuation were considered related to the study drug.

Date of Clinical Trial Report

09-Sep-2010